FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 THE AVONEX CHANNEL
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week
March 2005   
April 2005   
June 2005   
July 2005   
August 2005   
September 2005   
October 2005   
November 2005   
May 2006   
June 2006   
July 2006   
October 2006   
April 2010   
May 2013   
June 2013   
July 2013   
August 2013   
July 2014   
November 2014   
January 2015   
February 2015   
April 2015   
July 2015   
January 2016   
March 2016   

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Wednesday

 

Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in MS: TRACER study: STUDY







































Image Source: ABDEM
Read more »

Labels: , , ,


Sunday

 

Tecfidera (Dimethyl fumarate) treatment alters circulating T helper cell subsets in MS: STUDY




















Image Source: MYNEWSDESK
Read more »

Labels:


 

End-of-Year Task: Renewing Your DMT Prescription for 2016






























By Kim Dolce—December 8, 2015

December is upon us, and besides being the holiday season, ‘tis also the season to renew our prescriptions for disease-modifying therapies and reapply for co-pay assistance.
Read more »

Labels: , , , ,


 

Development of interferon beta-neutralising antibodies in MS—a systematic review and meta-analysis: STUDY





































Image Source: BETA-NEUTRALISINGANTIBODIES
Read more »

Labels: , ,


 

Adherence and cost in MS patients treated with IM IFN beta-1a: impact of the CARE patient management program: STUDY







































Image Source: SKYLIGHT
Read more »

Saturday

 

1200 People With Relapsing MS Needed For RPC1063, Avonex Clinical Trials























Clinical investigators worldwide are beginning to recruit 1,200 patients with relapsing multiple sclerosis for a study assessing the effectiveness of two different doses of RPC1063 (Receptos, Inc.), an experimental oral therapy, and Avonex® (interferon beta-1a, Biogen Inc.) in order to reduce relapse rate in patients. This study, called the Sunbeam Study, is being funded by Receptos, Inc.
Read more »

Labels:


Wednesday

 

FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments



This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.

DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY
Read more »

Labels: , , , , , , , ,


 

Oral Gilenya (Fingolimod) or Intramuscular Interferon for Relapsing Multiple Sclerosis: STUDY

Saturday

 

Acceptance of the Extracare Program by Beta Interferon-Treated Patients With Multiple Sclerosis: Results of the Explore Study: STUDY

 

This Could Be Game-Changing News in the Battle Against Multiple Sclerosis

























For a disease that affects more than 400,000 people in the United States and approximately 2.5 million around the globe, multiple sclerosis is arguably not getting its fair share of attention from drug developers and researchers. According to the National Institutes of Health, which has an annual budget near $40 billion, only $115 million is expected to be spent on MS research in 2015.
Read more »

Labels: , , , ,


Sunday

 

Requirement Allopathic treatments for Multiple Sclerosis.































Some treatments are designed to shorten the length of flare-ups or exacerbations. Still other medications are made use of to relive symptoms of MS either short-term or long term.
Read more »

Labels: ,


 

Multiple sclerosis market is arguably one of the most competitive in pharma





























The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in part by a handful of products (Avonex, Betaseron, Copaxone and Rebif) that are both effective, very well established and which deliver broadly comparable efficacy. In more recent years, an ´oral revolution´ has advanced the therapeutic optionality for MS patients, but simultaneously left room for further improvements.
Read more »

Labels: , ,


 

Viragen Announces That OVA(TM) System Results are Published in Leading U.S. Scientific Journal Viragen, Inc.

Viragen Announces That OVA(TM) System Results are Published in Leading U.S. Scientific Journal
Viragen, Inc.
(Amex: VRA; VRA.U; VRA.WS) and its collaborative partners in the field of
avian transgenics, Roslin Institute and Oxford Biomedica Plc (LSE: OXB),
today announced that the Proceedings of the National Academy of Sciences of
the United States of America (PNAS), a leading scientific journal, has
published an article profiling the OVA(TM) System's ability to express two
therapeutic proteins in the whites of eggs of transgenic hens. The OVA(TM)
System is being developed as a novel, large-scale biomanufacturing
alternative capable of cost-effectively expressing many types of
therapeutic proteins.

The article, entitled, "Oviduct-specific expression of two therapeutic
proteins in transgenic hens," reports on the production of two protein drug
candidates: a humanized monoclonal antibody being developed by Viragen for
advanced malignant melanoma; and interferon beta-1a, which is currently
marketed under two competing brand names for the treatment of Multiple
Sclerosis (MS), as Avonex(R)* (Biogen Idec) and Rebif(R)** (Serono).

Article Summary:
Recent advances in avian transgenesis have led to the possibility of
utilizing the laying hen as a production platform for the large-scale
synthesis of pharmaceutical proteins. Ovalbumin constitutes more than half
of the protein in the white of a laid egg, and expression of the ovalbumin
gene is restricted to the tubular gland cells of the oviduct. Here we
describe the use of lentiviral vectors to deliver transgene constructs
comprising regulatory sequences from the ovalbumin gene designed to direct
synthesis of associated therapeutic proteins to the oviduct. We report the
generation of transgenic hens that synthesize functional recombinant
pharmaceutical protein in a tightly regulated tissue-specific manner,
without any evidence of transgene silencing after germ-line transmission.
MORE

Labels:


 

Biogen Idec inc Earnings Were Great. Here's Why the Stock Tumbled Anyway

















There's nothing like the disclosure of a side effect to ruin a perfectly good earnings report. Despite meeting analyst expectations on revenue, and beating on the earnings-per-share side, Biogen Idec traded down more than 10% at one point today after announcing that a patient taking its oral multiple sclerosis drug Tecfidera contracted progressive multifocal leukoencephalopathy, or PML.
Read more »

Labels: , , ,


 

Plegridy approved by FDA for multiple sclerosis















The U.S. Food and Drug Administration (FDA) has approved Plegridy as the new multiple sclerosis treatment by Biogen Idec.
Read more »

Labels: , ,


 

Plans to introduce pen injection for Multiple Sclerosis patients back on track

















Procedures to introduce pen injections for patients suffering from Multiple Sclerosis (MS) should be concluded shortly, and will be distributed to patients once the previous formulation is exhausted, The Malta Independent is informed.
Read more »

 

Multiple sclerosis: What you need to know about the disease

 

Plans to introduce pen injection for Multiple Sclerosis patients back on track




















Procedures to introduce pen injections for patients suffering from Multiple Sclerosis (MS) should be concluded shortly, and will be distributed to patients once the previous formulation is exhausted, The Malta Independent is informed.
Read more »

 

Treatment Plan Should Include Education, Nutrition and Appropriate Medication



















There is as yet no cure for MS. Many patients do well with no therapy at all, especially since many medications have serious side effects and some carry significant risks. However, three forms of beta interferon (Avonex, Betaseron and Rebif) have now been approved by the Food and Drug Administration for treatment of relapsing-remitting MS.
Click here to read more

Labels: ,


 

Can Biogen Idec Take Wing With Tecfidera?





















Biogen Idec (NASDAQ:BIIB) generates most of its revenue from drugs for MS (multiple sclerosis), but also receives substantial sums from other disease indications. It recently has gained approval for its hemophilia therapies. Biogen has a high trailing P/E ratio, (38, at $342 per share) consistent with investors expecting continued EPS growth.
Read more »

Labels: , ,


 

FDA Approves Multiple Sclerosis Drug Plegridy


















On Friday, health regulators at the Food and Drug Administration (FDA) approved a new multiple sclerosis drug called Plegridy. The drug, created by Biogen Idec, is a long-acting multiple sclerosis formula that will likely replace the company’s Avonex treatment. Plegridy is meant to slow the progression of multiple sclerosis and reduce relapse rates.
Read more »

Labels: ,


 

MSNZ welcomes consultation period for Tysabri and Gilenya

 

NOVARTIS WILL PAY TO GET MSers TO USE GILENYA
























Novartis will pay out-of-pocket costs for non-Medicare patients who use Gilenya! PLUS:  Novartis will also help patients navigate testing and monitoring recommended by the FDA, paying as much as $600 per patient for that expense.
Read more »

Labels: , , ,


 

Gilyena gets a thumbs-up in Europe to go along with U.S. approval

 

Biogen unveils study results confirming effectiveness of new MS treatment Plegridy

Kate Dawson, VP of Medical
       Affairs at Biogen
Biogen presented follow-up data from the second year of patients taking Plegridy, a once-a-month or once-every-other-week injected drug awaiting an approval decision in the U.S. as well as Europe. In the study, Plegridy was shown to continue helping patients manage relapses versus a placebo.

U.S. regulators accepted Biogen’s application for approval of Plegridy last July, and recently extended its deadline to approve the drug by three months. A decision is expected in coming months.
Read more »

Labels: ,


 

GOOD NEWS ON TEVA'S NEW MS TREATMENT LAQUINIMOD (NERVENTRA)

 

Biotech Gets A Lift On Popular Drug, Strong Pipeline


















The success of Biogen Idec's oral multiple sclerosis (MS) treatment Tecfidera has been well documented in recent quarters, but the company is far from a one-hit wonder.
Read more »

Labels: , , ,


 

HERE'S MY TIPS ON HOW TO REDUCE THE TERRIBLE SIDE EFFECTS OF AVONEX & OTHER INTERFERONS
















Toni Perry, Guest Columnist, MSnewsChannel.com

I think we are the unknown hero's of multiple sclerosis. I myself was dx'd in 2000 at 27 years of age. I was put on avonex immediately. Many stop this therapy because of the side effects we all know that interferons cause. I can say that I have lost 24 hours a week to avonex. I run a fever and have extra fatigue and often extra pain and depression on what I call my medicine day. I've found there are ways to help myself. Take ibuprofen before my shot which my husband gives just before bed. I try to sleep through the fluish feelings. I take ibuprofen when I wake and it helps more than any thing I've been prescribed. I have not had a flare for many years and I will stay on avonex
Read more »

Labels: ,


 

Wow! It's no wonder MS is seen as a Cash Cow: THESE MS DRUGS BROUGHT IN THE MOST MONEY LAST YEAR

Teva soaring out in front on a single product and it is no surprise that the Generics pack are waiting in the rear ready for the copaxone patents to expire starting May 2014. However Biogen are backing the most winners with a staggering $5.8 billion worth of business. 
#1 Glaterimer acetate Teva     $4.3 billion
#2 Avonex Biogen Idec           $3.0 billion
#3 Gilenya Novartis                 $1.9 billion
#4 Tysabri Biogen  Idec           $1.7 billion
#5 Betaseron Bayer                 $1.1 billion
#6 Tecfidera Biogen Idec        $0.9 billion
#7 Rebif EMD serono              $0.6 billion
#8 Ampyra Biogen Idec           $0.3 billion
#9 Aubagio Sanofi                   $0.2 billion
#10 Extavia Novartis               $0.2 billion

Read more »

Labels: , , , , , , , , ,


 

Brain Volume Changes in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Avonex

The reductions in brain volume often seen in patients with chronic relapsing–remitting multiple sclerosis may be reduced by treatment according to Michael G. Dwyer, PhD, assistant professor of neurology in the Department of Neurology at the University of Buffalo School of Medicine and Biomedical Sciences, and the technical imaging director of the Buffalo Neuroimaging Analysis Center, Buffalo, NY
Click here to read

Labels:


 

Data Show Declining Use of Injectables as Oral Multiple Sclerosis Therapies Gain Traction

 

My secret to pain free Avonex shots plus my secret to coping with Avonex side effects


Yvonne Decelis, Columnist, MSnewsChannel.com

I have been on Avonex since 1998. I have found that the way (for me) to make the shots as "pain free" as I can is to use something like Prilocaine/Lidocaine cream (or Emla) to numb the top layer of skin out.

Here's how I cope with the side effects of Avonex
I really hope this helps you...

Read more »

Labels: ,


 

Yvonne Decelis, Columnist: Today is day 5 on the "full dose" (240mg) I THINK MY MEMORY IS SHOWING SIGNS OF IMPROVEMENT! The numbness & pain my hands has subsided quite a bit, my "migraine headache" this morning went away very quickly

Today is day 5 on the "full dose Tecfidera" (240mg so far) am having no side effects and it's AWESOME (a little tired of peanut butter but LOVE not losing my weekends. I can't wait to fully get over the Avonex withdrawal and waking up)!

The numbness and pain my hands has subsided quite a bit, my "migraine headache" this morning went away very quickly and I THINK my memory is showing signs of improvement (feeling "cautiously optimistic").


Read more »

Labels:


 

Biogen profit rises as Tecfidera shines

 

IS AVONEX GOOD OR BAD FOR PREGNANT MSers?

IS AVONEX GOOD OR BAD FOR PREGNANT MSers? HERE'S A NEW STUDY


BMJ Case Rep. 2014 Apr 7;2014. pii: bcr2013201273. doi: 10.1136/bcr-2013-201273.

Interferon β-1a therapy for multiple sclerosis during pregnancy: an unresolved issue
Abstract
On the basis of evidence from clinical trials, contraindications to the use of interferon (INF) are pregnancy, epilepsy and depression. Management of multiple sclerosis during pregnancy is a difficult issue because of pregnancy-related complications and fear of congenital anomalies due to exposure to disease-modifying therapy. In different series, INF therapy was withdrawn before or after variable periods of exposure. This case illustrates a 26-year-old woman diagnosed with relapsing remitting multiple sclerosis who was treated with a weekly regimen of intramuscular INF-β 1a (Avonex). She had received this treatment throughout her pregnancy without any further exacerbations of symptoms or any untoward pregnancy-related complications. In contrast to different series, our patient had the longest exposure to INF-β during pregnancy.

Story Source: The above story is based on materials provided by PUBMED
ote: Materials may be edited for content and length

Labels: ,


 

IMPORTANT UPDATE: "American specialists should also be aware of this worrisome but rare adverse effect, said MS expert Aaron Miller, MD, Icahn Mount Sinai School of Medicine, NYC"

Aaron Miller, MD,
Icahn Mount Sinai School of Medicine
New York City
Cases of unexpected, serious, and even fatal thrombotic microangiopathy (TMA) linked to use of a new serum-free formulation of interferon beta (Rebif) have emerged in patients with MS
In a Letter to the Editor published in the March 27 issue of the New England Journal of Medicine, David Hunt, PhD, from Edinburgh University, and colleagues reported on 4 such cases that were diagnosed in South Scotland during an 18-month period. Regulatory authorities in the United Kingdom received 6 additional spontaneous reports of disorders related to TMA and the same formulation of interferon beta, which was introduced in Europe in September 2007, the letter notes. 

The authors call for specialists to be on the lookout for signals of this rare adverse effect of interferon beta in their patients with MS.

Read more »

Labels: ,


 

Biogen Idec to Present New Clinical Data from Its Neurology Portfolio of Drugs at AAN Annual Meeting

 

Interferon β-1a therapy for multiple sclerosis during pregnancy: an unresolved issue

 

Multiple Sclerosis and Pregnancy: Current Considerations

 

Can new versions of Copaxone, Avonex drive market share retention?

 

HOW MS MEDICATIONS DIFFER FROM EACH OTHER

 

Heather Tetzlaff Smith, Columnist, MSnewsChannel.com

Heather Tetzlaff Smith

 “I have MS.” How many times have I said those words? How many different ways have I felt when I said it? And yet…I rarely say it anymore

It was sometime near the middle of October, 1998 when I received a call FROM the neurologist’s office.  Earlier that year I had become clumsy and was tripping over nothing and running into doorways as I entered and exited a room. A visit to my family doctor led to a referral to a neurologist which then led
Read more »

Labels:


 

biogens-winning-strategy? Biogen's share of that market was about 1/3 in recent years: With Tecfidera's launch & success the company is now able to increase that share

 

Tecfidera Captures the Largest U.S. Neurologist-Reported Patient Share Among Oral Disease-Modifying Multiple Sclerosis Therapies Ten Months Post-Launch

 

Biogen Idec: A Biotech Pioneer With A Stellar Future

 

BREAKING NEWS: FDA delays decision on Biogen's multiple sclerosis drug Plegridy

Biogen Idec Inc said the U.S. Food and Drug Administration extended the review process for the company's multiple sclerosis drug by three months to evaluate the application. Biogen, which was expecting to launch the drug, Plegridy, by mid-2014, said the FDA did not ask for additional studies.
Plegridy, is an injectable drug designed to reduce the dosing schedule of standard interferon drugs such as Biogen's own Avonex, which are typically dosed at least once a week. Interferon is hard to tolerate as it leads to flu-like symptoms, prompting patients to delay or discontinue treatment. Analysts say the market for such interferon-based treatments will shrink over the next decade as newer generation products enter the fray. More

Labels:


 

Tecfidera Is Off to a Quick Start

Saturday

 

Synthetic Biologics Announces Issuance of U.S. Patent patents for MS and other autoimmune diseases covering the uses of its oral estriol candidate, Trimesta

 

Yvonne Decelis, Columnist, MSnewsChannel.com

Yvonne Decelis
Insurance refusing to cover my Tecfidera

Hi there. For those of you who do not know me, my name is Yvonne Decelis and I have relapsing remitting MS.

Back in July of 2013 I went off of Avonex, my MS disease modifying drug (DMD) that I had been on since 1998.  I chose to switch to Tecfidera and as soon as it was available in the US I told my Neurologist to put me on it. Unfortunately, due to my insurance (Medicare Part D plan - Humana which I plan to change soon) refusing to cover it, I was off my DMD for 5 weeks. This unintended “medication vacation” made me quite a bit worse off physically. My fatigue became much more pronounced and I needed more sleep than I had in over a decade. It took me a long time to get over the med "break" and I never really fully recuperated.
Read more »

Labels:


 

Biogen Idec finished 2013 on a high note, with its highly touted oral multiple sclerosis drug Tecfidera producing nearly $400 million in sales during the fourth quarter

 

Another big beast joins the MS Drug fray: ofatumumab phase 2 trial results

"MS used to be a orphan disease. Interferon-beta-1a (Avonex) was licensed by the FDA under the orphan drug legislation. What is an orphan disease? Orphan diseases are rare diseases that only affect a small percentage of the population. Orphan drug acts were put in place  to incentivise drug companies to take the risk and develop drugs for these diseases. MS is no longer an orphan disease; sales of DMTs for MS are close to $15billion a year. In the beginning the Pharma companies in the MS space were relatively small, but as the market expanded the big beasts started to arrive; Novartis, Sanofi, Roche and now GSK. GSK is developing ofatumumab for MS; the stunning phase 2 results are presented below."

The Big Beast: GSK joins the fray
"Ofatumumab is a completely humanised monoclonal antibody that depletes B-cells by binding to CD20 on their surface. You will have noted that this is not a unique strategy and ofatumumab follows on the results of rituximab and ocrelizumab. In other words
Read more »

Labels:


 

THE AMAZING DOCTOR WHO WAS PART OF A TEAM WHO HELPED INVENT COPAXONE & REBIF & IS NOW FOCUSING ON STEM CELLS AT 75

 

FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments



This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.

DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY
Read more »

Labels: , , , , , , , , ,


 

15 STUDIES IN FRIDAY'S NEWS

 PLUS: 1590 new Studies we posted from 11/1 to Thursday 2/12 Start at the Bottom!


The NBSS, developed specifically to assess the symptoms and consequences associated with neurogenic bladder dysfunction, has appropriate psychometric properties. Depending on the measurement need, individual domains may be selected, or it can be used as a comprehensive score.

The fraction of intrathecally-produced VZV-specific IgG of the total intrathecally produced IgG discriminates between patients with VZV reactivation and MS. Our results provide further evidence that intrathecally-produced VZV antibodies are part of the polyspecific immune response in patients with MS.

 In addition to autoantigens implicated in thyroid autoimmunity, fibrocytes and derivative fibroblasts express multiple autoantigens associated with T1DM. This expression results from active gene promoters and abundant steady-state mRNA encoding ICA69 and IA-2. These latest findings demonstrate that fibrocytes express antigens relevant to multiple forms of endocrine autoimmunity. They suggest the potential for these cells playing a direct role in immune reactivity directed at the thyroid and pancreatic islets.

MMPs can also enhance the cleavage of myelin basic protein (MBP) and the demyelination process. Regarding the growing data on the roles of MMPs and their tissue inhibitors (TIMPs) in the pathogenesis of MS, this review discusses the role of different types of MMPs, including MMP-2, -3, -7, -9, -12 and -25, in the immunopathogenesis and treatment of MS.

In a real-world setting, patients with MS who switched from IFNs to fingolimod were significantly less likely to experience relapses than those who switched to GA.
Read Study Pubmed.gov



Read more »

Labels: , , , , , , , , , , ,


 

15 STUDIES IN THURSDAY'S NEWS

 PLUS: 1575 new Studies we posted from 11/1 to Wednesday 2/12 Start at the Bottom!




In patients with SSc, serum levels of ICAM-1 and P-selectin may serve as prognostic indicators of respiratory dysfunction and physical disability, respectively. Further longitudinal studies of larger populations are needed to confirm these findings.

Seizures can occur at any stage during the course of MS, but it is more common during the early stages.

In a real-world setting, patients with MS who switched from IFNs to fingolimod were significantly less likely to experience relapses than those who switched to GA.

In the NARCOMS cohort, functional health literacy is high. However, lower levels of health literacy are associated with adverse health behaviors and greater health care utilization.
Read Study at Pubmed.gov

In the pathogenesis of MS, this review discusses the role of different types of MMPs, including MMP-2, -3, -7, -9, -12 and -25, in the immunopathogenesis and treatment of MS.
Read Study at Pubmed.gov

Read more »

Labels: , , , , , , , , , , ,


 

15 STUDIES IN WEDNESDAY'S NEWS

 PLUS: 1560 new Studies we posted from 11/1 to Tuesday 2/11 Start at the Bottom!



Seminal data regarding its use in MS, the known mechanism(s) of action, and contemporary studies focusing on efficacy and safety data will be reviewed. The role of chemotherapeutic agents in the management of MS and implications for therapeutic intervention are also discussed. 
Read Study at Pubmed.gov

The best current evidence for the efficacy of glucocorticoid treatment in MS, by far, comes from the optic neuritis treatment trial, which used high-dose intravenous methylprednisolone for the first 3 days followed by an 11-day course of low-dose oral prednisone. 
Read Study at Pubmed.gov

It is hoped that, through an understanding of the earliest aspects of the MS disease process, critical insights will be gained about the genesis of MS. 
Read Study at Pubmed.gov

Major technical improvements in MRI hardware and pulse sequence design allow more specific and potentially more sensitive treatment metrics required for targeting outcomes most relevant to neuronal degeneration, remyelination and repair. 
Read Study at Pubmed.gov

This chapter reviews the current evidence, taken from both clinical and paraclinical sources, as it relates to establishing this prognosis and provides insight to where, in the future, we need to look. 
Read Study at Pubmed.gov

Read more »

Labels: , , , , , , , , ,


 

15 STUDIES IN TUESDAY'S NEWS

 PLUS: 1545 new Studies we posted from 11/1 to Monday 2/10 Start at the Bottom!



These findings support previous systematic reviews, however publication bias cannot be excluded. The methodological conduct of studies could be improved, particularly with regard to reporting and conduct of laboratory analyses.
Read Study at Pubmed.gov

Despite the long follow-up, the risk of MS appears lower in New South Wales children compared to previously reported cohorts. Radiological features are more predictive than clinical features in predicting MS. The McDonald 2010 criteria performed well although the dissemination in time criteria on baseline scans is difficult to apply to children with encephalopathy.
Read study at Pubmed.gov

Our findings suggest that higher CR in individuals with MS may mediate between cognitive performance and brain pathology. CR-related compensation may, however, fail with progression of damage. The time window of opportunity for therapeutic approaches aimed at intellectual enhancement most likely lies in the earliest disease stages.
Read Study at Pubmed.gov

Further evidence of vitamin D deficiency as a causal factor, its molecular targets in MS and its prospect as a therapeutic and preventative agent are questions that warrant further study.
Read Study at Pubmed.gov

Patients with ≥2 relapses annually have higher resource utilization and costs. The difference in cost was over twice as large in treatment-naïve patients versus treatment-experienced patients. HRA was also associated with an increased likelihood of starting DMT treatment (treatment-naïve patients), and switching or discontinuing DMT therapy (treatment-experienced patients).
Read Study at Pubmed.gov 

Read more »

Labels: , , , , , , , , ,


 

15 STUDIES IN MONDAY'S NEWS

 PLUS: 1530 new Studies we posted from 11/1 to Sunday 2/9 Start at the Bottom!

Farming and exposure to livestock may be important factors in the development of FCD among women, with this finding further revealed after the confounding effect of parity or number of children is considered.
Read Study at Pubmed.gov

Results suggest that demyelinated lesions in MS mainly have a remote effect on the thalamus and that the measurement of CBF using ASL could be an objective marker for monitoring disease activity in MS.
Read Study at Pubmed.gov

Here, we summarize currently accepted therapeutic principles and the drugs in late stages of development, as well as spotlighting potential novel openings for future research.
Read Study at Pubmed.gov

Collaboration between neurologists and psychiatrists whilst caring for patients displaying neuropsychiatric manifestations of MS is crucial to enable more accurate diagnoses and try to improve treatment and overall prognosis. 
Read Study at Pubmed.gov

In summary, in this retrospective analysis, daclizumab therapy substantially decreased the rate of brain atrophy in relapsing-remitting MS in comparison to other disease-modifying therapies, predominantly interferon β.
Read Study at Pubmed.gov

Read more »

Labels: , , , , , , , , ,


 

15 STUDIES IN SUNDAY'S NEWS

 PLUS: 1515 new Studies we posted from 11/1 to Saturday 2/8 Start at the Bottom!


In this paper we present a new unsupervised approach addressing this problem with dictionary learning and sparse coding methods. We show its general applicability to the problem of lesion segmentation by evaluating our approach on synthetic and clinical image data and comparing it to state-of-the-art methods.
Read Study at Pubmed.gov

In this paper we will review the substantial literature regarding experimental and clinical use of these stem cells and possible mechanisms in the treatment of MS. These results may pave the road for the utilization of stem cells for the treatment of MS.
Read Study at Pubmed.gov

Long walking tests and patient-reported MSWS-12 were more appropriate than short walking tests in detecting clinically meaningful improvement after physical rehabilitation, particularly the MSWS-12 for moderate to severely disabled pwMS.
Read Study at Pubmed.gov

The use of patient self-assessed outcome measures that appraise the quality of diagnosis communication is also important to allow health services to understand and meet the needs and preferences of PwMS.
Read Study at Pubmed.gov

Quantitative gait assessment reveals subtle gait disorders in patients with low disability of relapsing-remitting multiple sclerosis. The impact of different cognitive domains on gait induces specific gait disturbances that highlight the strong interaction between gait and cognition.
Read Study at Pubmed.gov

Read more »

Labels: , , , , , , , , ,


 

15 STUDIES IN SATURDAY'S NEWS

 PLUS: 1500 new Studies we posted from 11/1 to Friday 2/7 Start at the Bottom!


Studies are needed to further clarify why suicide ideation and suicidal behavior are associated with neurological diseases, in order to improve quality of life, alleviate patient distress, and prevent nonfatal and fatal suicide attempts in veteran and non-veteran populations.
Read Study at Pubmed.gov

Obesity in childhood or adolescence is associated with an increased risk of pediatric-onset and adult-onset multiple sclerosis
Read Study at Pubmed.gov

Autoimmune disorders are rare, but some of them tend to occur together with MS at a higher rate than in controls. Although women are generally more prone to ADs than men, significantly increased occurrence of other ADs were only found in male MS patients.
Read Study at Pubmed.gov

Paternal MS and MS-related clinical factors were not significantly associated with birth outcomes (p>0.05). This study provides assurance to expecting fathers with MS and their families.
Read Study at Pubmed.gov

This study showed that PET imaging of demyelination and remyelination processes in focal lesions is feasible.
Read Study at Pubmed.gov

Read more »

Labels: , , , , , , , , ,


 

15 STUDIES IN FRIDAY'S NEWS

 PLUS: 1485 new Studies we posted from 11/1 to Thursday 2/6 Start at the Bottom!

A study was done to assess the cost-effectiveness of the Disease Modifying Treatments (DMT), Glatiramer Acetate (GA) and Interferon beta-1a (IFN) in monotherapy alone and in combination for the prevention of relapses among Spanish patients aged between 18 and 60 years old with established Relapsing-Remitting Multiple Scerosis (RRMS).
Read Study at Pubmed.gov

Article reviews the current understanding of the interactions between multiple sclerosis (MS) and pregnancy, and implications for reproductive counseling. This is a key topic in MS because the typical patient is a young woman of childbearing age.Pregnancy has a profound effect on MS disease activity. Identification of the responsible mechanisms for this effect should lead to new disease insights and therapeutic strategies. 
Read Study at Pubmed.gov

Pain-related mood influences pain perception differently in fibromyalgia and multiple sclerosis.
Read Study at Pubmed.gov

Gait disorders need to be identified and managed early in the course of MS, using a multimodal approach that needs to be adjusted over time based on the results of periodic assessments.
Read Study at Pubmed.gov

Fatigue needs to be recognized as an important condition that is not only a symptom but may also be quantified and can be modified by various measures depending on the underlying cause.
Read Study at Pubmed.gov

Read more »

Labels: , , , , , , , , ,


 

15 STUDIES IN THURSDAY'S NEWS

PLUS: 1470 new Studies we posted from 11/1 to Wendnesday 2/5 Start at the Bottom! 



Current guidelines have recognized the benefits of early treatment of MS with DMTs. However, there are a number of barriers to implementing early MS treatment. Early diagnosis and treatment of MS can be hindered because patients may delay consulting a physician about their neurological symptoms or may be reluctant to start DMT. Read study at National Institute of Health

Due to the current lack of appropriate clinical guidance and insufficient head-to-head data on disease-modifying drugs, strategies for health plans and clinical management have been designed using the best available evidence. Undoubtedly, management of this class will continue to evolve with the launch of newer agents.
Read study at National Center for Biotechnology Information


A period of diagnostic uncertainty regarding the transition from RRMS to SPMS existed in many of our patients. Potential reasons included the subtle nature of early progressive disease and caution in applying a progressive label, in light of the lack of evidence-based treatments as well as third-party payer concerns. Delay in definitive identification of an SPMS phenotype has a variety of implications related to patient care and research.
Read study at National Center for Biotecnology Information

This study supports the concept that modifications of the tear proteome can reflect biological abnormalities associated with multiple sclerosis and perhaps other inflammatory conditions affecting the CNS. In addition, alpha-1-antichymotrypsin elevation in tear fluid emerges as a promising biomarker for the diagnosis of multiple sclerosis.

The present study examined the functioning of explicit and implicit memory in MS. Results showed that implicit memory was not significantly impaired in the MS subjects, and that they were impaired on recall but not recognition. A correlation was found between implicit memory performance and disability status in MS patients. 


Read more »

Labels: , , , , , , , , ,


 

15 STUDIES IN WEDNESDAY'S NEWS

 

15 STUDIES IN TUESDAY'S NEWS

PLUS: 1440 new Studies we posted from 11/1 to Monday 2/2 Start at the Bottom! 



Magnetic susceptibility of MS lesions increased rapidly as it changed from enhanced to nonenhanced, it attained a high susceptibility value relative to NAWM during its initial few years (approximately 4 years), and it gradually dissipated back to susceptibility similar to that of NAWM as it aged, which may provide new insight into pathophysiologic features of MS lesions.

In a cohort with different stages of MS, higher EA attenuated the negative effects of white matter lesion burden and third ventricle width (suggestive of thalamic atrophy) on cognitive performance. Actively enhancing cognitive reserve might thus be a means to reduce or prevent cognitive problems in MS in parallel to disease modifying drugs.

These data suggest that retrograde (trans-synaptic) axonal degeneration stops at the inner nuclear layer, a neuronal network capable of plasticity. In contrast, there seems to be no neuroplasticity of the primary visual cortex, rendering the structure vulnerable to anterograde (trans-synaptic) degeneration.

Simultaneous characterizations of changes in tonic and phasic reflexes and nonreflex changes in joint elastic stiffness and viscosity in neurological disorders may help us gain insight into mechanisms underlying spasticity and develop impairment-specific treatment.

Very rapid functional changes in the excitability of cortical circuits involved in motor control can be induced by steroids, before any process of remyelination or axonal regeneration has time to occur. The net effect of steroids on the balance between intracortical GABAergic inhibition and glutamatergic facilitation was in favour of weaker inhibition or stronger facilitation, which could lead to improving the motor performance in MS patients.

Read more »

Labels: , , , , , , , , ,


 

15 STUDIES IN MONDAY'S NEWS

PLUS: 1425 new Studies we posted from 11/1 to Sunday 2/2 Start at the Bottom! 



The majority of Italian neurologists participating in our study have a good perception of their ability to manage this difficult communicating process and believe in the great effect this moment may have on a life-long disease experience. Improving communication skills may help the therapeutic alliance, enhancing patients' acceptance of the disease, as well as motivation and adherence to treatment.

It is possible that, with further such supportive data, international guidelines on MS treatment in young women who intend to get pregnant may need to be revised.

A significant interaction between Alerting and Executive Control was also found in the MS patients (p = .007). Early relapsing-remitting multiple sclerosis particularly affects the Alerting domain of attention, whereas the Orienting and Executive Control domains are not affected.

The GM is atrophic in MS. Although lower WM volume is associated with greater disability, as might be expected, WM volume was on average in the normal range. This paradoxical result might be explained by the presence of coexisting pathological processes, such as tissue damage and repair, that cause both atrophy and hypertrophy and that underlie the observed disability.

ApEn results revealed that the natural fluctuations present during gait in the stride length and step width time series are more regular and repeatable in patients with MS. These changes implied that patients with MS may exhibit reduced capacity to adapt and respond to perturbations during gait.


Read more »

Labels: , , , , , , , , ,


 

15 STUDIES IN SUNDAY'S NEWS

PLUS: 1410 new Studies we posted from 11/1 to Saturday 2/1 Start at the Bottom! 


In this small, uncontrolled pilot study, there was a significant improvement in fatigue in those who completed the study. Given the small sample size and completer rate, further evaluation of this multimodal therapy is warranted.

These data suggest that retrograde (trans-synaptic) axonal degeneration stops at the inner nuclear layer, a neuronal network capable of plasticity. In contrast, there seems to be no neuroplasticity of the primary visual cortex, rendering the structure vulnerable to anterograde (trans-synaptic) degeneration.

The number of patients becoming pregnant during fingolimod therapy remains small and does not permit firm conclusions to be drawn about fetal safety of fingolimod in humans. Given the known risks of teratogenicity in animals and the present data, women of childbearing potential should use effective contraception during fingolimod therapy and for 2 months after discontinuation.

The relapse rate in children with multiple sclerosis is higher than in adult-onset disease. Following acute treatment, recovery after the first attacks is usually excellent, but patients with childhood-onset multiple sclerosis reach permanent disability or enter the secondary progressive disease course 10 years younger than patients with adult-onset multiple sclerosis.

Currently, various pharmacological agents such as antiepielptics, non-steroidal anti-inflammatory agents, and even corticosteroids are used to suppress various painful conditions associated with MS. Non-pharmacological procedures such as massage therapy have also been used in the treatment of MS patients. The authors present a review of recent findings in pathophysiology and management of pain in MS patients.

Read more »

Labels: , , , , , , , , ,


 

15 STUDIES IN SATURDAY'S NEWS

 

15 STUDIES IN FRIDAY'S NEWS

PLUS: 1380 new Studies we posted from 11/1 to Thursday 1/30 Start at the Bottom! 


Magnetic susceptibility of MS lesions increased rapidly as it changed from enhanced to nonenhanced, it attained a high susceptibility value relative to NAWM during its initial few years (approximately 4 years), and it gradually dissipated back to susceptibility similar to that of NAWM as it aged, which may provide new insight into pathophysiologic features of MS lesions.

In a cohort with different stages of MS, higher EA attenuated the negative effects of white matter lesion burden and third ventricle width (suggestive of thalamic atrophy) on cognitive performance. Actively enhancing cognitive reserve might thus be a means to reduce or prevent cognitive problems in MS in parallel to disease modifying drugs.

Grey matter damage - global and regional - has the potential to become a marker of disease activity, complementary to the currently used magnetic resonance markers (global brain atrophy and T2 hyperintense lesions). Furthermore, it may improve the prediction of the future disease course and response to therapy in individual patients and may also become a reliable additional surrogate marker of treatment effect.

results confirm the important role of the immune system and specifically B cells in MS and suggest that MS risk variants exert a gene regulatory role. Previous studies assessing MS risk variants in T cells may be missing important effects in B cells. Similar analyses in other immunological cell types relevant to MS and functional studies are necessary to fully elucidate how genes contribute to MS pathogenesis.

Fatigue management program outcomes for people with MS are moderated by age, gender, and impairment.
Read more »

Labels: , , , , , , , , ,


 

15 STUDIES IN THURSDAY'S NEWS

PLUS: 1365 new Studies we posted from 11/1 to Wednesday 1/29 Start at the Bottom! 


Employment status was an explanatory variable for physical health and mental health in the younger patients. EDSS played a significant role in physical health for all patients. A vocational rehabilitation program could prevent eventual nonemployment and improve health outcomes in older MS people.

Simultaneous characterizations of changes in tonic and, phasic reflexes and nonreflex changes in joint elastic stiffness and, viscosity in neurological disorders may help us gain insight into, mechanisms underlying spasticity and develop impairment-specific, treatment.

Using an active prospective surveillance system and the McDonald criteria for first MS diagnosis the age-related incidence of pediatric MS in Germany was uncovered and is more common than in previous estimates. Thorough application of McDonald criteria and inclusion of spinal MRI data allowed for early diagnosis in almost 90% of cases.

A high prevalence of urinary symptoms and urodynamic dysfunctions in patients with CISs and an association of urinary symptoms with quality of life measures were found. These results highlight the importance of identifying and optimally treating urinary symptoms also at the very early stages of MS.

The inflammatory mechanisms associated with lesion formation in MS are to a large extent reflected in experimental models of inflammatory demyelination, such as autoimmune encephalomyelitis. This is not the case for the amplification mechanisms of oxidative injury, which mainly operate in the progressive stage of the disease. GLIA 2014.
Read more »

Labels: , , , , , , , , ,


 

15 STUDIES IN WEDNESDAY'S NEWS